Protocol Ledger

NCT04061512 · Phase II/III · RECRUITING

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Interventional Phase II/III clinical trial protocol NCT04061512 sponsored by University College, London in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-03 Enrollment: 148 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04061512
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)148 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04061512
Protocol FieldVerified Registry Value
NCT IdentifierNCT04061512
Consolidated Lead SponsorUniversity College, London
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment148 participants (ESTIMATED)
Registered Start Date2020-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04061512
Hospital Research SiteLocationSite Profile
University Hospital of WalesCardiff, United KingdomOpen Hospital Dossier ->
Leicester Royal InfirmaryLeicester, United KingdomOpen Hospital Dossier ->
Barts Health NHS TrustLondon, United KingdomOpen Hospital Dossier ->
King's College HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI